Aegis Life
Aegis Life is a San Diego-based biotechnology company developing DNA-encoded monoclonal antibody therapeutics on its proprietary Fusogenix PLV gene therapy platform, targeting infectious diseases such as HIV, malaria, and influenza in global health settings.
- Company typePrivate
- Founded2020
- HeadquartersSan Diego, United States
- Headcount11–50
- GTM typeB2B
- OfferingHardware or Manufacturing
Aegis Life firmographics
Firmographics- Name
- Aegis Life
- Website
- https://aegis.life
- Company type
- Private
- Founded year
- 2020
- Operating status
- Operating
- Headcount range
- 11–50 employees
- Short description
- Aegis Life is a San Diego-based biotechnology company developing DNA-encoded monoclonal antibody therapeutics on its proprietary Fusogenix PLV gene therapy platform, targeting infectious diseases such as HIV, malaria, and influenza in global health settings.
- Ownership category
- akta.pro rank
Aegis Life industry classification
Industry- Product category
- Infectious Disease Therapeutics
- NAICS
- Research and Development in Biotechnology (except Nanobiotechnology) (541714)
- SIC
- Biological Products, (No Disgnostic Substances) (2836)
- akta.pro primary industry
- AAV Vector Gene Therapy Developers (HLAAACAA)
Keywords
Where Aegis Life is headquartered
LocationHeadquarters
- HQ city
- San Diego
- HQ country
- United States
- HQ region
- North America
Markets served
Aegis Life business model
Business model- GTM type
- B2B
- Offering type
- Hardware or Manufacturing
- Cost components
- Technology or R&D, Personnel, Operations
Revenue model
- Grant Funding: The company operates through grant funding from foundations such as the Bill & Melinda Gates Foundation to support R&D of infectious disease therapeutics.
Aegis Life product offering
Product offeringCore offering
Aegis Life develops DNA-encoded monoclonal antibody therapeutics for infectious diseases such as HIV, malaria, and influenza using its proprietary Fusogenix PLV gene therapy platform. The platform is intended to produce cost-effective antibody therapies directly inside patients' cells, reducing traditional manufacturing requirements and improving accessibility in low-resource global health settings. The company is currently pre-commercial and operates through R&D partnerships and grant funding.
Differentiator
Problem solved
Functional benefit
Products and services
- Fusogenix PLV Platform The Fusogenix PLV Platform is a proprietary gene therapy platform used to develop DNA-encoded monoclonal antibody therapeutics that produce cost-effective antibody treatments directly inside patients' cells, with initial programs targeting HIV, malaria, and influenza in global health settings.
Quantifiable outcome
- Reduce costs and increase accessibility of antibody treatments globally
Companies that use Aegis Life
Customer profileSegments1 record
Ideal customer profiles1 record
Aegis Life technology and API
TechnologyTechnology focussed Yes
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
Feature1 record
Aegis Life partnerships and signals
Strategic signalPartnerships
One partnership is on record.
- Entos PharmaceuticalscoreAegis Life and Entos Pharmaceuticals are collaborating on developing DNA-encoded monoclonal antibody therapies for infectious diseases including HIV, influenza, and malaria using the Fusogenix PLV platform. The partnership aims to leverage combined expertise in gene therapy and antibody development.
Scale indicators1 record
Aegis Life competitors and assessment
Company assessmentDirect peers
- Vir Biotechnology: Vir Biotechnology develops monoclonal antibody and engineered immune-based therapeutics for serious infectious diseases including HIV and influenza, overlapping directly with Aegis Life's target indications. Both companies apply antibody-based modalities to global infectious disease challenges.
- AbCellera Biologics: AbCellera is an antibody discovery platform company that partners with pharmaceutical firms to develop mAbs for infectious diseases. Both Aegis Life and AbCellera sit at the intersection of antibody technology and infectious disease therapeutic development.
- Entos Pharmaceuticals: Entos Pharmaceuticals is Aegis Life's strategic co-development partner and shares the Fusogenix PLV proteolipid vesicle platform. Entos develops nucleic acid therapeutics including DNA-encoded antibodies, making it the most directly comparable company by technology, platform, and target indications (HIV, influenza, malaria).
Broad incumbents
- Eli Lilly: Eli Lilly is a global biopharmaceutical company with a leading monoclonal antibody franchise, including infectious disease antibodies (e.g., COVID-19 neutralizing antibodies). It represents a broad incumbent whose mAb manufacturing and global distribution capabilities contrast with Aegis Life's in-vivo alternative.
- BioNTech: BioNTech develops mRNA-based therapeutics for infectious diseases (notably influenza and HIV programs) and is actively exploring nucleic acid–encoded antibodies. It is a broad incumbent pursuing the same nucleic-acid-delivered antibody space as Aegis Life, with far greater resources and pipeline depth.
- Regeneron Pharmaceuticals: Regeneron is a major monoclonal antibody developer with significant infectious disease programs (including Ebola and COVID-19 antibodies). It is a broad incumbent whose antibody platform and global health engagement overlap thematically with Aegis Life's mAb focus.
- Moderna: Moderna is a leading mRNA platform company with an infectious disease focus (including influenza and emerging pandemic preparedness) and is actively developing nucleic acid–delivered antibodies. It is a broad incumbent in nucleic-acid-based infectious disease therapeutics that overlaps with Aegis Life's technology approach.
- Gilead Sciences: Gilead is a leading antiviral and infectious disease company with a dominant HIV franchise and active programs in influenza and other viral diseases. It is a broad incumbent whose therapeutic focus and global health engagement overlap with Aegis Life's target indications.
- ViiV Healthcare: ViiV Healthcare is a global specialist HIV company majority-owned by GSK, focused exclusively on HIV therapeutics and treatment access. It is a broad incumbent addressing the same HIV indication Aegis Life targets, with established global health distribution networks.
Emerging players
- Adagene: Adagene is a clinical-stage biotechnology company developing novel antibody therapeutics using computational and platform-based discovery. It is an emerging player in antibody platform development with overlapping technology-driven approach to differentiated mAbs.
Market position
Customer concentration
Aegis Life financial estimates
Financial estimateRevenue estimate
Valuation estimate
Aegis Life leadership team
Management profileNumber of profiles
Profiles2 records
Aegis Life funding detail
Funding detailFunding overview
Funding rounds3 records
Investors4 records
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
Aegis Life M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about Aegis Life
What does Aegis Life do?
Aegis Life develops DNA-encoded monoclonal antibody therapeutics for infectious diseases such as HIV, malaria, and influenza using its proprietary Fusogenix PLV gene therapy platform. The platform is intended to produce cost-effective antibody therapies directly inside patients' cells, reducing traditional manufacturing requirements and improving accessibility in low-resource global health settings. The company is currently pre-commercial and operates through R&D partnerships and grant funding.
When was Aegis Life founded?
Aegis Life was founded in 2020. It employs 11 to 50 people.
Where is Aegis Life based?
Aegis Life is headquartered in San Diego, United States, in the North America region.
How does Aegis Life make money?
One revenue line is on record: grant Funding.
Who are Aegis Life's main competitors?
Direct peers on record are Vir Biotechnology, AbCellera Biologics and Entos Pharmaceuticals. Broad incumbents are Eli Lilly, BioNTech, Regeneron Pharmaceuticals, Moderna, Gilead Sciences and ViiV Healthcare. Adagene is listed as an emerging player.
Does Aegis Life have an API?
No public API is recorded for Aegis Life.
What industry is Aegis Life in?
Aegis Life's product category is Infectious Disease Therapeutics. Its primary akta.pro industry code is HLAAACAA, AAV Vector Gene Therapy Developers. Its NAICS code is 541714 and its SIC code is 2836.